Loading...

Chimeric Therapeutics Limited

CHM.AXASX
Healthcare
Biotechnology
A$0.003
A$-0.00(-25.00%)

Chimeric Therapeutics Limited (CHM.AX) Stock Competitors & Peer Comparison

See (CHM.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CHM.AXA$0.00-25.00%9.7M-0.15-A$0.02N/A
CSL.AXA$264.05-2.60%131.2B32.44A$8.35+1.57%
TLX.AXA$20.15-2.56%7.1B150.36A$0.14N/A
MSB.AXA$2.35-4.08%3B-12.53-A$0.19N/A
NEU.AXA$16.93+1.80%2.1B15.86A$1.09N/A
CU6.AXA$4.46+3.00%1.4B-27.31-A$0.16N/A
OPT.AXA$0.60+0.00%738.8M-1.28-A$0.47N/A
PYC.AXA$1.21-5.10%723.2M-11.27-A$0.11N/A
CUV.AXA$12.43-3.12%650.1M16.84A$0.77+0.39%
IMM.AXA$0.26-1.89%396.3M-9.00-A$0.03N/A
Showing 1 to 10 of 57 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CHM.AX vs CSL.AX Comparison August 2025

CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CHM.AX stands at 9.7M. In comparison, CSL.AX has a market cap of 131.2B. Regarding current trading prices, CHM.AX is priced at A$0.00, while CSL.AX trades at A$264.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CHM.AX currently has a P/E ratio of -0.15, whereas CSL.AX's P/E ratio is 32.44. In terms of profitability, CHM.AX's ROE is -4.24%, compared to CSL.AX's ROE of +0.15%. Regarding short-term risk, CHM.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;